Medexus Pharmaceuticals
Medexus Pharmaceuticals is a specialty pharmaceutical company focused on the North American market. It develops, markets, and distributes a portfolio of therapies addressing rare diseases, autoimmune conditions, pediatric needs, oncology, and allergy. The company’s products include Rasuvo and Metoject (methotrexate) for rheumatoid arthritis and other autoimmune diseases; IXINITY for Hemophilia B; Rupall for seasonal and perennial allergic rhinitis and chronic spontaneous urticaria; Cuvposa for sialorrhea in children with neurologic conditions; Gliolan for intraoperative visualization of brain tumors; and Treosulfan as a conditioning agent before stem cell transplantation. Its operations span Canada and the United States, supported by a North American commercial platform that sells to wholesalers, distributors, healthcare facilities, and specialty pharmacies. Originally known as Pediapharm, the company rebranded as Medexus in 2018 and is based in Verdun, Canada.
Top Stages
3 past transactions
Aptevo Therapeutics
Acquisition in 2020
Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics. It leverages its proprietary ADAPTIR platform technology to create immunotherapeutic candidates, with lead products including IXINITY for hemophilia B and APVO436 in Phase 1/1b trials for acute myeloid leukemia.
Medexus Pharmaceuticals
Acquisition in 2018
Medexus Pharmaceuticals is a specialty pharmaceutical company focused on the North American market. It develops, markets, and distributes a portfolio of therapies addressing rare diseases, autoimmune conditions, pediatric needs, oncology, and allergy. The company’s products include Rasuvo and Metoject (methotrexate) for rheumatoid arthritis and other autoimmune diseases; IXINITY for Hemophilia B; Rupall for seasonal and perennial allergic rhinitis and chronic spontaneous urticaria; Cuvposa for sialorrhea in children with neurologic conditions; Gliolan for intraoperative visualization of brain tumors; and Treosulfan as a conditioning agent before stem cell transplantation. Its operations span Canada and the United States, supported by a North American commercial platform that sells to wholesalers, distributors, healthcare facilities, and specialty pharmacies. Originally known as Pediapharm, the company rebranded as Medexus in 2018 and is based in Verdun, Canada.
Medac Pharma
Acquisition in 2018
Medac Pharma specializes in the development and treatment of cancer, autoimmune diseases, and urological diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.